文献速递炎症性肠病

炎症性肠病中焦虑与抑郁轨迹的特征及影响

Characteristics and Effect of Anxiety and Depression Trajectories in Inflammatory Bowel Disease.
PubMed 文献 · Am J Gastroenterol · 2022-10-12

该研究在12个月随访中对771例和777例炎症性肠病患者每3个月进行问卷调查,发现焦虑或抑郁评分恶化或持续异常者抗抑郁药与阿片类药物使用更多、基线疾病活动度更高、生活质量更低,且门诊、影像学和内镜检查使用更多,但未来不良疾病结局风险未增加。

要点

  • 焦虑或抑郁评分恶化或持续异常的炎症性肠病患者抗抑郁药及阿片类药物使用率更高。
  • 这些患者更常见近12个月内诊断炎症性肠病、基线临床活动性疾病及较低生活质量评分。
  • 焦虑或抑郁轨迹恶化或持续异常者门诊、影像学和内镜检查更多,但未来不良疾病结局风险未增加。

核心结论

  • 在12个月随访中,焦虑或抑郁评分恶化或持续偏高的炎症性肠病患者是医疗服务的高使用人群,但未来不良疾病结局风险未增加。

研究设计与样本

  • 前瞻性随访研究,在12个月内每3个月通过问卷调查收集人口学、症状、心理和生活质量数据,并通过病历回顾收集医疗服务使用和炎症性肠病结局。
  • 焦虑分析纳入771例患者,抑郁分析纳入777例患者。

主要发现

  • 焦虑评分恶化或持续异常组 vs 持续正常或改善组:抗抑郁药使用28.6% vs 12.3%,阿片类药物使用19.0% vs 7.8%(P=0.001),近12个月内诊断炎症性肠病16.3% vs 5.0%(P=0.001),基线临床活动性疾病57.1% vs 26.6%(P<0.001)。
  • 抑郁评分恶化或持续异常组 vs 持续正常或改善组:抗抑郁药使用35.8% vs 10.1%,阿片类药物使用34.0% vs 7.4%,近12个月内诊断炎症性肠病15.1% vs 5.5%(P=0.006),基线临床活动性疾病71.7% vs 29.1%(P<0.001)。
  • 焦虑和抑郁评分恶化或持续异常组的生活质量评分均较低(P<0.001)。
  • 焦虑或抑郁轨迹恶化或持续异常的患者因炎症性肠病相关症状需要更多的门诊预约、影像学检查和内镜操作。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Symptoms of common mental disorders, such as anxiety or depression, are associated with adverse clinical outcomes in inflammatory bowel disease (IBD). We report trajectories of these symptoms in IBD, patient characteristics associated with different trajectories, and effects on healthcare utilization and prognosis. METHODS: We collected demographic, symptom, psychological, and quality-of-life data, with questionnaires at 3-month intervals, over 12 months of follow-up. We collected healthcare utilization and IBD outcomes through notes review. We compared characteristics of those with persistently normal or improving anxiety or depression scores with those with persistently abnormal or worsening scores and the number of flares, glucocorticosteroid prescriptions, escalations of therapy, hospitalizations, or intestinal resections due to IBD activity. RESULTS: Among 771 and 777 patients, respectively, worsening or persistently abnormal anxiety or depression scores were associated with increased antidepressant (28.6% vs 12.3% anxiety, 35.8% vs 10.1% depression, P < 0.001) and opiate use (19.0% vs 7.8% anxiety, P = 0.001 and 34.0% vs 7.4% depression, P < 0.001), compared with those with persistently normal or improving scores. These individuals were also more likely to have been diagnosed with IBD in the last 12 months (16.3% vs 5.0% anxiety, P = 0.001, and 15.1% vs 5.5% depression, P = 0.006), to have clinically active disease at baseline (57.1% vs 26.6% anxiety and 71.7% vs 29.1% depression, P < 0.001) and lower quality-of-life scores ( P < 0.001). Individuals with worsening or persistently abnormal trajectories of anxiety or depression required significantly more outpatient appointments, radiological investigations, and endoscopic procedures for IBD-related symptoms. DISCUSSION: In this 12-month follow-up study, patients with IBD with worsening or persistently high anxiety or depression scores were higher utilizers of health care but were not at an increased risk of future adverse disease outcomes.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Fairbrass KM, Guthrie EA, Black CJ, et al. Characteristics and Effect of Anxiety and Depression Trajectories in Inflammatory Bowel Disease. Am J Gastroenterol. 2022. PMID: 36227779. doi:10.14309/ajg.0000000000002063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。